WO2021050564A3 - Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders - Google Patents
Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders Download PDFInfo
- Publication number
- WO2021050564A3 WO2021050564A3 PCT/US2020/049965 US2020049965W WO2021050564A3 WO 2021050564 A3 WO2021050564 A3 WO 2021050564A3 US 2020049965 W US2020049965 W US 2020049965W WO 2021050564 A3 WO2021050564 A3 WO 2021050564A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lyme disease
- methods
- therapeutic agents
- related disorders
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Disclosed herein are methods of reducing inflammation in subjects having Borrelia infections and related disorders, the methods including administering therapeutic agents to the subjects and measuring inflammatory and immune markers.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962899134P | 2019-09-11 | 2019-09-11 | |
US62/899,134 | 2019-09-11 | ||
US201962923519P | 2019-10-19 | 2019-10-19 | |
US62/923,519 | 2019-10-19 | ||
US202062983467P | 2020-02-28 | 2020-02-28 | |
US62/983,467 | 2020-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021050564A2 WO2021050564A2 (en) | 2021-03-18 |
WO2021050564A3 true WO2021050564A3 (en) | 2021-04-22 |
Family
ID=74870039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/049965 WO2021050564A2 (en) | 2019-09-11 | 2020-09-09 | Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021050564A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115308313A (en) * | 2021-05-08 | 2022-11-08 | 成都倍特药业股份有限公司 | Method for detecting acetaldehyde in potassium clavulanate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017124080A1 (en) * | 2016-01-17 | 2017-07-20 | Jayakumar Rajadas | Methods and drug compositions for treating lyme disease |
-
2020
- 2020-09-09 WO PCT/US2020/049965 patent/WO2021050564A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017124080A1 (en) * | 2016-01-17 | 2017-07-20 | Jayakumar Rajadas | Methods and drug compositions for treating lyme disease |
Non-Patent Citations (1)
Title |
---|
CALLISTER ET AL.: "Detection of IFN-gamma Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease", CLIN INFECT DIS., vol. 62, no. 10, 15 May 2016 (2016-05-15), pages 1235 - 1241, XP008182255, DOI: 10.1093/cid/ciw112 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021050564A2 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019032662A8 (en) | Clec9a binding agents and use thereof | |
PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
WO2020252418A3 (en) | Novel interleukin-2 variants for the treatment of cancer | |
WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
SG10201809947UA (en) | Use of prg4 as an anti-inflammatory agent | |
WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
MY171929A (en) | Corticosteroids for the treatment of joint pain | |
NO20050807L (en) | Pharmaceutical compositions including dextromethorphan and quinidine for the treatment of neurological disorders | |
MX2021010058A (en) | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders. | |
WO2021021979A3 (en) | Hdac6 inhibitors and uses thereof | |
MX2021002321A (en) | Novel methods. | |
MX2019012086A (en) | Compositions and methods for treating or preventing gut permeability-related disorders. | |
MX2021003681A (en) | Benzimidazole derivative for use in the treatment of inflammatory disorders. | |
PH12019502874A1 (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
PH12020551905A1 (en) | C-mannoside compounds useful for the treatment of urinary tract infections | |
WO2021050564A3 (en) | Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders | |
BR112015001859A2 (en) | inflammation treatment using serelaxine | |
DE602005010844D1 (en) | PHARMACEUTICAL COMPOSITIONS WITH INTERFERON TAU | |
WO2015048188A3 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20862116 Country of ref document: EP Kind code of ref document: A2 |